Canada markets closed

CSPC Pharmaceutical Group Limited (CVG.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
0.7442-0.0016 (-0.21%)
At close: 08:01AM CEST
Full screen
Previous Close0.7458
Bid0.7336 x 1500000
Ask0.7752 x 1500000
Day's Range0.7442 - 0.7442
52 Week Range0.6226 - 0.8750
Avg. Volume3,400
Market Cap9.003B
Beta (5Y Monthly)0.70
PE Ratio (TTM)12.40
EPS (TTM)0.0600
Earnings DateMay 27, 2024
Forward Dividend & Yield0.03 (4.43%)
Ex-Dividend DateMay 31, 2024
1y Target EstN/A
  • Reuters

    FOCUS-China's drugmakers can't sell mRNA shots but haven't quit yet

    China's vaccine developers stuck with unused mRNA COVID shots and idle manufacturing plants are pursuing new targets for the novel messenger RNA technology, but they face a tough path, crimped by a lack of revenue. Three Chinese companies - Walvax Biotechnology, CSPC Pharmaceutical Group and Stemirna Therapeutics - came up with mRNA vaccines that won limited emergency approvals in Asia. However, Walvax and CSPC are not currently manufacturing three of their China market shots, a China health official told Reuters.

  • Reuters

    UPDATE 1-China's CSPC Pharma partners with Pfizer for oral COVID treatment

    Chinese drug maker CSPC Pharmaceutical Group said on Thursday it signed a strategic partnership with Pfizer to launch a local brand of an oral COVID-19 treatment, in an attempt to improve the access for treatment in China. The combination of Nirmatrelvir and Ritonavir sold under the brand name Paxlovid, an oral small molecule developed by pharmaceutical company Pfizer, is used to treat patients suffering from mild to moderate COVID-19 symptoms and who are at the risk of disease progression. China, whose home-grown vaccines are seen as less effective than the Moderna and Pfizer-BioNTech mRNA shots, has been racing to develop vaccines using messenger RNA (mRNA) technology since early 2020.